Polpharma European CDMO Partner & API Manufacturer since 1951 Polpharma European CDMO Partner & API Manufacturer since 1951

X

Find Entospletinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

0

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

EU WC

EU WC

0

Listed Suppliers

Listed Suppliers

0

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Entospletinib
Also known as: 1229208-44-9, Gs-9973, 6-(1h-indazol-6-yl)-n-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine, Entospletinib [inn], Entospletinib (gs-9973), Gs9973
Molecular Formula
C23H21N7O
Molecular Weight
411.5  g/mol
InChI Key
XSMSNFMDVXXHGJ-UHFFFAOYSA-N
FDA UNII
6I3O3W6O3B

Entospletinib is an orally available inhibitor of spleen tyrosine kinase (Syk), with potential antineoplastic activity. Upon oral administration of entospletinib, this agent may inhibit the activity of Syk, which inhibits B-cell receptor (BCR) signaling and leads to an inhibition of tumor cell activation, migration, adhesion and proliferation. Syk, a non-receptor cytoplasmic, BCR-associated tyrosine kinase, is expressed in hematopoietic tissues and is often overexpressed in hematopoeitic malignancies.
1 2D Structure

Entospletinib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
6-(1H-indazol-6-yl)-N-(4-morpholin-4-ylphenyl)imidazo[1,2-a]pyrazin-8-amine
2.1.2 InChI
InChI=1S/C23H21N7O/c1-2-17-14-25-28-20(17)13-16(1)21-15-30-8-7-24-23(30)22(27-21)26-18-3-5-19(6-4-18)29-9-11-31-12-10-29/h1-8,13-15H,9-12H2,(H,25,28)(H,26,27)
2.1.3 InChI Key
XSMSNFMDVXXHGJ-UHFFFAOYSA-N
2.1.4 Canonical SMILES
C1COCCN1C2=CC=C(C=C2)NC3=NC(=CN4C3=NC=C4)C5=CC6=C(C=C5)C=NN6
2.2 Other Identifiers
2.2.1 UNII
6I3O3W6O3B
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 6-(1h-indazol-6-yl)-n-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine

2. Gs-9973

2.3.2 Depositor-Supplied Synonyms

1. 1229208-44-9

2. Gs-9973

3. 6-(1h-indazol-6-yl)-n-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine

4. Entospletinib [inn]

5. Entospletinib (gs-9973)

6. Gs9973

7. 6i3o3w6o3b

8. Chembl3265032

9. Syk Inhibitor Gs-9973

10. 6-(1h-indazol-6-yl)-n-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine

11. Imidazo(1,2-a)pyrazin-8-amine, 6-(1h-indazol-6-yl)-n-(4-(4-morpholinyl)phenyl)-

12. 6-(1h-indazol-6-yl)-n-(4-morpholin-4-ylphenyl)imidazo[1,2-a]pyrazin-8-amine

13. 6-(1h-indazol-6-yl)-n-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine

14. Entospletinib [usan:inn]

15. Unii-6i3o3w6o3b

16. 4puz

17. Imidazo[1,2-a]pyrazin-8-amine, 6-(1h-indazol-6-yl)-n-[4-(4-morpholinyl)phenyl]-

18. Gs 9973

19. Gs9973entospletinib

20. Gs-9973; Entospletinib

21. Entospletinib (usan/inn)

22. Entospletinib [usan]

23. Entospletinib [who-dd]

24. Gtpl7889

25. Schembl2483776

26. Dtxsid001317670

27. Hms3653d13

28. Hms3673e05

29. Hms3750e13

30. Amy14224

31. Bcp09582

32. Ex-a1120

33. Bdbm50015448

34. Mfcd28099806

35. Nsc781516

36. Nsc800988

37. S7523

38. Zinc98208742

39. Akos027295322

40. Ccg-264700

41. Db12121

42. Nsc-781516

43. Nsc-800988

44. Sb16830

45. Ncgc00378596-07

46. Ac-30236

47. As-17026

48. Da-36929

49. Hy-15968

50. Ft-0700130

51. Sw220048-1

52. D11209

53. A890877

54. J-690079

55. Q27077193

56. Entospletinib;6-(1h-indazol-6-yl)-n-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine

57. 6-cyclopropyl-8-fluoro-2-[2-(hydroxymethyl)-3-(1-methyl-5-{[5-(4-methyl-1-piperazinyl)-2-pyridinyl]amino}-6-oxo-1,6-dihydro-3-pyridi Nyl)phenyl]-1(2h)-isoquinolinone

2.4 Create Date
2012-08-20
3 Chemical and Physical Properties
Molecular Weight 411.5 g/mol
Molecular Formula C23H21N7O
XLogP33.6
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count6
Rotatable Bond Count4
Exact Mass411.18075832 g/mol
Monoisotopic Mass411.18075832 g/mol
Topological Polar Surface Area83.4 Ų
Heavy Atom Count31
Formal Charge0
Complexity595
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Treatment of acute myeloid leukaemia


Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY